Repligen Corporation (RGEN)
NASDAQ: RGEN · IEX Real-Time Price · USD
123.81
-3.82 (-2.99%)
At close: Jul 19, 2024, 4:00 PM
124.19
+0.38 (0.31%)
Pre-market: Jul 22, 2024, 7:36 AM EDT
Repligen Revenue
Repligen had revenue of $607.45M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $151.35M. In the year 2023, Repligen had annual revenue of $638.76M.
Revenue (ttm)
$607.45M
Revenue Growth
-21.90%
P/S Ratio
11.39
Revenue / Employee
$340,690
Employees
1,783
Market Cap
6.92B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 638.76M | -162.77M | -20.31% |
Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
Dec 31, 2019 | 270.25M | 76.21M | 39.28% |
Dec 31, 2018 | 194.03M | 52.80M | 37.38% |
Dec 31, 2017 | 141.24M | 36.70M | 35.10% |
Dec 31, 2016 | 104.54M | 21.00M | 25.14% |
Dec 31, 2015 | 83.54M | 19.99M | 31.45% |
Dec 31, 2014 | 63.55M | -4.62M | -6.78% |
Dec 31, 2013 | 68.17M | 5.90M | 9.48% |
Dec 31, 2012 | 62.27M | 34.98M | 128.16% |
Mar 31, 2011 | 27.29M | 6.32M | 30.14% |
Mar 31, 2010 | 20.97M | -8.39M | -28.58% |
Mar 31, 2009 | 29.36M | 10.07M | 52.16% |
Mar 31, 2008 | 19.30M | 5.22M | 37.10% |
Mar 31, 2007 | 14.07M | 1.16M | 9.01% |
Mar 31, 2006 | 12.91M | 3.55M | 37.94% |
Mar 31, 2005 | 9.36M | 2.45M | 35.38% |
Mar 31, 2004 | 6.91M | -857.44K | -11.03% |
Mar 31, 2003 | 7.77M | 3.47M | 80.67% |
Mar 31, 2002 | 4.30M | 2.05M | 90.74% |
Mar 31, 2001 | 2.26M | -648.72K | -22.34% |
Mar 31, 2000 | 2.90M | 526.46K | 22.14% |
Mar 31, 1999 | 2.38M | -7.57K | -0.32% |
Mar 31, 1998 | 2.38M | -1.42M | -37.26% |
Mar 31, 1997 | 3.80M | -7.06M | -64.99% |
Mar 31, 1996 | 10.86M | -6.08M | -35.91% |
Mar 31, 1995 | 16.94M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jazz Pharmaceuticals | 3.84B |
Exelixis | 1.85B |
Penumbra | 1.10B |
Halozyme Therapeutics | 862.99M |
Ionis Pharmaceuticals | 776.62M |
Tempus AI | 562.02M |
Ascendis Pharma | 357.63M |
Blueprint Medicines | 282.21M |
RGEN News
- 6 days ago - Repligen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 25 days ago - This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
- 4 weeks ago - Top 3 Health Care Stocks That Could Blast Off In June - Benzinga
- 5 weeks ago - Repligen Announces CEO Transition Plan - GlobeNewsWire
- 6 weeks ago - Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing - Business Wire
- 2 months ago - Repligen Corporation to Present at Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Repligen Corporation to Present at Upcoming May Investor Conferences - GlobeNewsWire
- 2 months ago - Repligen Reports First Quarter 2024 Financial Results - GlobeNewsWire